Shanghai, November 10, 2025 — The 8th China International Import Expo (CIIE) concluded successfully today. As a regular participant, Bayer, a global leader in life sciences, took the mission, “Health for All, Hunger for None,” as its theme and participated for the eighth consecutive year with its three divisions: Pharmaceuticals (and Radiology), Consumer Health, and Crop Science. At this year's CIIE, Bayer presented 26 highlight innovative exhibits, signed over 10 strategic cooperation agreements, held and participated in more than 50 events.
“Congratulations on the successful conclusion of the 8th CIIE! I am thrilled that Bayer has once again forged valuable new connections through this platform, taking significant strides in our journey of innovation and collaboration,” said Zhou Xiaolan, Executive Vice President, Pharmaceuticals Division, Bayer AG, President of Bayer Pharmaceuticals China, President of Bayer China. “As an important platform for promoting high-standard opening-up and high-quality development, the CIIE continues to generate a powerful ‘spillover effect,’ empowering Bayer to deepen our roots and thrive in China by collaborating with all partners from diverse sectors. Looking ahead, Bayer is committed to being a collaborative builder and enabler of China’s innovation ecosystem, working with Chinese partners to create an innovation community that embodies the spirit of ‘In China, For the World’.”
Notably, during the 8th CIIE, a delegation led by Wu Zhengping—Deputy Director of the CIIE Bureau—visited Bayer’s booth. They presented Bayer China with the “8-Year Full Attendance” medal in recognition of its long-standing positive contributions to the CIIE in the fields of health and nutrition, as the company participated in the expo for the eighth consecutive year. Ms. Sue Wang, Vice President of Public Affairs and Sustainability, Bayer China, accepted the honor on behalf of Bayer. This award reflects the CIIE Bureau’s high recognition of Bayer’s long-term support for the CIIE and its continuous efforts to promote opening-up and cooperation.
Launching Innovations to Meet Global Challenges
At this year’s CIIE, Bayer showcased the depth and tangible progress of its innovation strategy through multi-dimensional and multi-tiered releases of innovative products and cutting-edge research. These breakthroughs and advancements will provide wisdom and solutions to address global challenges in the fields of healthcare and agriculture.
In Pharmaceuticals, Bayer focuses on key areas including oncology, cardiovascular diseases, ophthalmology, and women health, continuously expanding its product pipeline and services to advance diagnostics and treatment. At CIIE this year, Eylea® 8mg, which recently received approval in China, held its national launch media conference. Groundbreaking research findings, including the VICTOR study results for vericiguat and Expert Consensus on Comprehensive Prostate Cancer Management (2025 Edition), were unveiled. At the same time, to address the multi-faceted health needs of women, Bayer introduced a series of initiatives to provide comprehensive health solutions across their all-life stages. These included the CIIE debut of Elizanetant, which is a hormonal-free treatment for menopausal-related hot flashes, the launch of Al-empowered treatment solutions in women health, the release of a new 84-tablet pack size for Yasmin, and the brand renewal of Mirena with its updated positioning as the intrauterine drug delivery system.
In Consumer Health, Bayer unveiled multiple Global Debuts at the CIIE focusing on health needs in allergy, digestion, skincare and nutrition which includes its latest baby skincare innovation - Bepanthen Nappy Rash Ointment. It partnered leading dermatology experts to share cutting-edge research and clinical applications of Pro-Vitamin B5, underscoring the commitment to providing consumers with scientific, safe, and effective skincare solutions.
In Crop Science, Bayer hosted brand events at its dual booths (1.2H & 8.1H), highlighting recently launched innovations. These included De Lai - the crop performance enhancers brand, featuring two flagship products, seven new DEKALB corn seed varieties, and the new corn seed brand Nong Bei Le, which demonstrates Bayer’s innovation strategy of being deeply rooted in local markets while leveraging global resources.
Advancing Partnerships for a New Healthcare Ecosystem
The CIIE has established itself as a key platform for Bayer to foster industrial collaboration and build ecosystems. Through more than ten high-level strategic signings and ecosystem development initiatives, Bayer looks forward to building an open, collaborative innovation network with its partners from various sectors, paving new paths for future clinical practice and market application to advance the high-quality development of China's healthcare industry.
In Pharmaceuticals, Bayer joined industry partners to sign the Prostate Cancer Life Cycle Management COE Project and the Prostate Cancer Quality Control Enhancement Initiative, comprehensively enhancing the diagnosis and treatment standards as well as patient management quality of China's prostate cancer care. Furthermore, Bayer signed a cooperation agreement with the Beijing Humanoid Robot Innovation Center Co., Ltd., and committed to advancing the technological development of humanoid robots and embodied AI for applications in solid drug manufacturing, packaging, quality control, warehousing, and logistics. Additionally, strategic agreements were signed with partners including Huaxia Ophthalmology Hospital Group, Beijing Municipal Affiliated Hospital, and the Boao Lecheng International Medical Tourism Pilot Zone Administration, broadening the frontiers of medical innovation. Moreover, Bayer actively addresses women's health needs in China and aligns with national population policy directions by deepening and expanding its Women’s Health Ecosystem. At the forum themed “Expanding the Ecosystem, Empowering Her Era,” the Digital Empowerment for Village Doctors Project, jointly initiated by Bayer Foundation and the United Nations Population Fund (UNFPA), was officially launched. This project aims to enhance the gynecological diagnosis and treatment capabilities of village doctors through digital tools, promoting more equitable and accessible health services for women. At the same time, Bayer established partnerships with leading tech platforms including JD Health and Ali Health to further refine the ecosystem's service framework, offering users more convenient and professional health support.
In Radiology, Bayer collaborated with the Radiology Department of Peking University Shenzhen Hospital to utilize the high-pressure injector Centargo's Smart Protocol for precise control, and in combination with Radimetrics radiation dose management software to optimize diagnostic experience and enhance clinical benefits for atrial fibrillation patients.
In Consumer Health, Bayer actively embraces the innovation opportunities presented by AI technology. At the AI for Self-care Management event, Bayer announced an expanded collaboration with MATWINGS Technology in applying AI technology to scientific research, new product development, and application transformation. Meanwhile, Bayer Consumer Health renewed its strategic partnership with Shandong Jewim Pharmaceutical to explore and develop self-care solutions suitable for Chinese consumers through innovative models such as joint research and development and contract manufacturing.
Expanding Access to Shape the Future of Healthcare
True accessibility to health and well-being transcends product availability to encompass understandable knowledge, changeable behaviors, and accessible services. At this year's CIIE, Bayer combined immediate actions with forward-looking strategies, not only disseminating health and agricultural knowledge through innovative science outreach but also laying the groundwork for future ecosystems via long-term cooperation.
On the front of science education, Bayer has made specialized knowledge more accessible and engaging for the public. In Pharmaceuticals (and Radiology), in addition to education activities such as the roundtable themed “CKM Panorama: Shaping a New Paradigm for Integrated Comorbidity Care,” and Lung Cancer Precision Treatment Forum, Bayer also held the celebration for the first anniversary of New BayAspirin and the educational seminar on cardiovascular health. By leveraging innovative AI technology, Bayer created a dialogue transcending time and space and officially released the Cardiovascular Health Management Manual: Myocardial Infarction and Cerebral Infarction to empower health education with technology and raise public awareness of cardiovascular diseases. Meanwhile, through the International Day of Radiology event on November 8th, Bayer conducted science communication in diagnostic imaging to improve public understanding of contrast enhancement and the use of consumables. In Consumer Health, Bayer provided the live science popularization broadcast with experts in the field of allergy and the health education centered around the CIIE debut of Talcid Lactulose Oral Solution to translate specialized knowledge in allergy treatment and digestive health into practical public health guidance, demonstrating Bayer’s commitment to safeguarding national health through its diverse product portfolio. In Crop Science, Bayer featured interactive tastings of diverse vegetable varieties and displays of fresh corn plants, attracting numerous visitors to experience the innovative “fruits” of its agricultural advancements.
Looking to the future, Bayer has established several key partnerships and strategies aimed at continuously improving the healthcare service system. For instance, Bayer Pharmaceuticals and China Charity Federation celebrated the 10-year cooperation on Hemophilia COPAY Charity Project, further expanding access to innovative medicines. Bayer Consumer Health signed a new five-year strategic cooperation agreement with Shanghai Pharmaceuticals, focusing on business development and market expansion to make Bayer's high-quality products accessible to more Chinese consumers. Addressing the health needs of younger generations, Bayer Pharmaceuticals launched a youth-oriented branding strategy for Yasmin and deepened the Women Health Knowledge Education Initiative to focus and protect future fertility.
Moving forward hand in hand is the path to a shared future. With the conclusion of this CIIE as a new starting point, Bayer will continue to grow in sync with China, using innovation as its brush and cooperation as its ink to paint a healthier, brighter tomorrow on the grand blueprint of Healthy China and Rural Revitalization.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of healthcare and agriculture. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
